<?xml version="1.0" encoding="UTF-8"?>
<p>It was originally produced in Japan and used more frequently in China; due to its teratogenic effect, in Japan its use is only allowed during the evolution of emerging epidemics or infections. In SARS-Cov-2 infection, favipiravir was more effective in viral eradication and regression of lung imaging than both lopinavir/ritonavir and of umifenovir. However, it can only be given to women who are not pregnant (
 <xref rid="B59" ref-type="bibr">59</xref>).
</p>
